HemoSonics’ Quantra Hemostasis System Earns Silver at the 2026 Edison Awards for Advancing Obstetric Care HemoSonics LLC, a medical device innovator specializing in acute bleeding management, has earned significant industry recognition for its advancements in maternal healthcare. The company announced…
Niagen Bioscience Unveils Niagen Plus Telehealth Platform with New At-Home Injection Kit Offering Niagen Bioscience (NASDAQ: NAGE), widely recognized for its leadership in NAD+ (nicotinamide adenine dinucleotide) research and its focus on advancing the science of healthy aging, has announced…
Armatus Unveils Scalable Potency Assay Platform to Advance Next-Generation Gene Silencing Therapies Armatus Bio, a late-preclinical biotechnology company focused on developing vectorized RNA interference (RNAi) therapies for neuromuscular disorders, has announced the publication of new research in Molecular Therapy Advances…
Satellite Bio Secures U.S. Food and Drug Administration Rare Pediatric Disease Designation for SB-101 in Urea Cycle Disorders Satellite Biosciences has announced a significant regulatory milestone, revealing that the U.S. Food and Drug Administration has granted Rare Pediatric Disease (RPD)…
Orthogon Therapeutics Secures Additional $11M to Advance BK Virus Antiviral Drug Program Orthogon Therapeutics has announced the successful close of an additional $11 million in follow-on financing, bringing the company’s total capital raised to $36 million. The new funding will…
Canadian Association of Optometrists Marks Vision Health Month with “GetEyeWise” Digital Awareness Campaign The Canadian Association of Optometrists is once again placing eye health in the national spotlight through its annual public education initiative, encouraging Canadians to take a closer…
Agendia to Showcase New Evidence Supporting Expanded Use of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Congress Agendia Inc., a leader in genomic testing for breast cancer, has announced the presentation of new clinical data at the European…
Corcept’s Phase 2 Trial of Dazucorilant Shows Sustained Two-Year Survival Advantage in ALS Patients Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on developing therapies that modulate cortisol activity, has reported new long-term data from its Phase 2…
U.S. FDA Accepts Priority Review for Gilead’s Once-Daily HIV Therapy Combining Bictegravir and Lenacapavir Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational once-daily, single-tablet regimen combining…
Study Reveals Growing Public Optimism for Scientific Breakthroughs Amid Increasing Concerns Over the Pace of Global Change A new global report developed by Leaps by Bayer in collaboration with Boston Consulting Group and Ipsos UK sheds fresh light on how…
Samsung Bioepis and ATLATL Enter MoU to Advance Early-Stage Biotech Innovation Across Asia-Pacific Samsung Bioepis Co., Ltd. has entered into a strategic collaboration with ATLATL Innovation Center to strengthen early-stage biotechnology innovation across the Asia-Pacific region. The two organizations announced…
Genexine’s First-in-Class SOX2 Degrader GX-BP1 Achieves Up to 96% Tumor Growth Inhibition and Prevents Regrowth in Preclinical Studies Genexine, Inc., a clinical-stage biotechnology firm focused on next-generation therapeutic platforms, has reported new preclinical findings for its innovative oncology candidate GX-BP1.…